



## **Notice Concerning Non-operational Expenses**

Nagoya, Japan, May 15, 2024 – RaQualia Pharma Inc. (headquartered in Nagoya; President & CEO: Hirobumi Takeuchi, “Company”) hereby announces that the Company records non-operational expenses for the first quarter of the fiscal year ending December 31, 2024 (January 1, 2024 to March 31, 2024) as follows:

### **1. Non-operating Expenses as Syndication Fees**

In the first quarter of the fiscal year ending December 31, 2024, the Company entered into a syndicated loan agreement as of March 21, 2024, and recorded 140 million yen in non-operating expenses as syndication fees.

### **2. Impact on Business Forecast**

The Company will not revise its full-year consolidated earnings forecast for the fiscal year ending December 31, 2024 (January 1, 2024 to December 31, 2024), which was announced on February 14, 2024, at this time, but if revisions to the forecast become necessary, the Company will make an announcement as soon as they are determined.